Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion and keeping the price target at $16.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis has given his Buy rating due to a combination of factors including the promising clinical data from the CLEAR Outcomes Trial and the ongoing commercial success of Esperion’s product. The trial results have shown significant reductions in LDL-C and major adverse cardiovascular events (MACE) among statin-intolerant patients, which highlights the potential of bempedoic acid as an effective treatment option.
Moreover, the continued commercial uptake, evidenced by the U.S. product revenue of $87.3 million, indicates a strong market presence and growing acceptance among healthcare providers. These factors, coupled with the attention the trial has garnered from physicians, underscore the potential for further growth and expansion in the treatment of high-risk cardiovascular patients.
Pantginis covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Esperion, and Travere Therapeutics. According to TipRanks, Pantginis has an average return of 2.2% and a 44.09% success rate on recommended stocks.
In another report released on November 6, Needham also maintained a Buy rating on the stock with a $4.00 price target.